Novo Nordisk 20. Apr. 2026 Novo Nordisk to seek oral sickle cell therapy approval after Phase III victory - Yahoo
Novo Nordisk 20. Apr. 2026 Novo Nordisk Details Progress of DKK 15 Billion Share Buyback Programme - TipRanks
Novo Nordisk 20. Apr. 2026 Novo readies SCD drug from $1.1B Forma buyout for approval push after phase 3 win - Fierce Biotech
Novo Nordisk 20. Apr. 2026 Novo posts trial win for sickle cell disease drug (NVO:NYSE) - Seeking Alpha
Novo Nordisk 17. Apr. 2026 Eli Lilly's Pill Lags Novo Nordisk's In First Week. Why Stock Rallied. - Investor's Business Daily